Format

Send to

Choose Destination
Haematologica. 2019 Sep;104(9):e398-e401. doi: 10.3324/haematol.2018.211615. Epub 2019 Feb 21.

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.

Author information

1
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon bazarbac@aub.edu.lb.
2
Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
3
Acute Leukemia Working Party of EBMT, Paris, France.
4
Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
5
Hôpital Saint Antoine, Université Pierre and Marie Curie, INSERM, UMRs 938, Paris, France.
6
Hematology Department, Federico II University of Naples, Naples, Italy.
7
University Hospital, Hematology, Basel, Switzerland.
8
Hôpital Saint Louis, Department of Hematology - BMT, Paris, France.
9
CHU Bordeaux Hôpital Haut-leveque, Pessac, France.
10
Programme de Transplantation and Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
11
CHU Nantes, Department D'Hematologie, Nantes, France.
12
CHRU, Service des Maladies du Sang, Angers, France.
13
Department of Hematology, Rotterdam, the Netherlands.
14
Tor Vergata University of Rome, Stem Cell Transplant Unit, Policlinico Universitario Tor Vergata, Rome, Italy.
15
CHU CAEN, Institut d'Hématologie de Basse-Normandie, Caen, France.
16
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
17
Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
18
Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center